Presented in this report are in vitro laboratory data and findings from several clinical observations supporting the hypothesis that SGRM-induced upregulation of SSTR2 by relacorilant may enhance tumor localization via SSTR imaging and may also sensitize tumors to the antitumor effects of somatostatin and its analogs. The gene discussed is SSTR2; the disease is neoplasm.